Go Pro
→ Major Buy Alert Issued for August 31st (From TradeSmith) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Chemomab Therapeutics Ltd. Sponsored ADR stock logo
CMMB
Chemomab Therapeutics
$2.09
+9.4%		$1.72
$1.35
▼
$4.12
$13.75M0.6559,786 shs118,763 shs
Skye Bioscience, Inc. stock logo
SKYE
Skye Bioscience
$0.31
-14.8%		$0.63
$0.28
▼
$4.99
$12.72M2.971.02 million shs1.38 million shs
Senti Biosciences, Inc. stock logo
SNTI
Senti Biosciences
$0.46
+7.6%		$0.70
$0.33
▼
$2.88
$13.40M2.1197,311 shs207,103 shs
UNITY Biotechnology, Inc. stock logo
UBX
UNITY Biotechnology
$0.20
$0.43
$0.20
▼
$1.23
$3.44M0.92808,608 shsN/A
10 Stocks Powering The Next AI Boom Cover
10 Stocks Powering The Next AI Boom

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Chemomab Therapeutics Ltd. Sponsored ADR stock logo
CMMB
Chemomab Therapeutics
+9.42%+8.85%+39.33%+14.84%-43.82%
Skye Bioscience, Inc. stock logo
SKYE
Skye Bioscience
-14.79%-44.27%-53.20%-57.20%-90.81%
Senti Biosciences, Inc. stock logo
SNTI
Senti Biosciences
+7.65%+23.40%+6.73%-52.95%-71.06%
UNITY Biotechnology, Inc. stock logo
UBX
UNITY Biotechnology
0.00%0.00%0.00%0.00%+11.79%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Chemomab Therapeutics Ltd. Sponsored ADR stock logo
CMMB
Chemomab Therapeutics
$2.09
+9.4%		$1.72
$1.35
▼
$4.12
$13.75M0.6559,786 shs118,763 shs
Skye Bioscience, Inc. stock logo
SKYE
Skye Bioscience
$0.31
-14.8%		$0.63
$0.28
▼
$4.99
$12.72M2.971.02 million shs1.38 million shs
Senti Biosciences, Inc. stock logo
SNTI
Senti Biosciences
$0.46
+7.6%		$0.70
$0.33
▼
$2.88
$13.40M2.1197,311 shs207,103 shs
UNITY Biotechnology, Inc. stock logo
UBX
UNITY Biotechnology
$0.20
$0.43
$0.20
▼
$1.23
$3.44M0.92808,608 shsN/A
10 Stocks Powering The Next AI Boom Cover
10 Stocks Powering The Next AI Boom

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Chemomab Therapeutics Ltd. Sponsored ADR stock logo
CMMB
Chemomab Therapeutics
+9.42%+8.85%+39.33%+14.84%-43.82%
Skye Bioscience, Inc. stock logo
SKYE
Skye Bioscience
-14.79%-44.27%-53.20%-57.20%-90.81%
Senti Biosciences, Inc. stock logo
SNTI
Senti Biosciences
+7.65%+23.40%+6.73%-52.95%-71.06%
UNITY Biotechnology, Inc. stock logo
UBX
UNITY Biotechnology
0.00%0.00%0.00%0.00%+11.79%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Chemomab Therapeutics Ltd. Sponsored ADR stock logo
CMMB
Chemomab Therapeutics
2.00
Hold$25.001,096.17% Upside
Skye Bioscience, Inc. stock logo
SKYE
Skye Bioscience
2.20
Hold$8.002,515.23% Upside
Senti Biosciences, Inc. stock logo
SNTI
Senti Biosciences
2.75
Moderate Buy$10.002,059.83% Upside
UNITY Biotechnology, Inc. stock logo
UBX
UNITY Biotechnology
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest UBX, CMMB, SNTI, and SKYE Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/5/2026
Chemomab Therapeutics Ltd. Sponsored ADR stock logo
CMMB
Chemomab Therapeutics
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E+)
7/17/2026
Senti Biosciences, Inc. stock logo
SNTI
Senti Biosciences
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E+)
7/10/2026
Skye Bioscience, Inc. stock logo
SKYE
Skye Bioscience
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D-)
(Data available from 8/20/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Chemomab Therapeutics Ltd. Sponsored ADR stock logo
CMMB
Chemomab Therapeutics
N/AN/AN/AN/A$2.00 per shareN/A
Skye Bioscience, Inc. stock logo
SKYE
Skye Bioscience
N/AN/AN/AN/A($0.01) per shareN/A
Senti Biosciences, Inc. stock logo
SNTI
Senti Biosciences
$20K721.12N/AN/A($0.11) per share-4.21
UNITY Biotechnology, Inc. stock logo
UBX
UNITY Biotechnology
N/AN/AN/AN/A$0.39 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Chemomab Therapeutics Ltd. Sponsored ADR stock logo
CMMB
Chemomab Therapeutics
-$8.99M-$2.22N/AN/AN/AN/A-89.03%-79.68%8/20/2026 (Estimated)
Skye Bioscience, Inc. stock logo
SKYE
Skye Bioscience
-$55.92M-$1.27N/AN/AN/AN/A-329.08%-201.79%N/A
Senti Biosciences, Inc. stock logo
SNTI
Senti Biosciences
-$61.44M-$1.77N/AN/AN/AN/A-1,629.80%-119.72%N/A
UNITY Biotechnology, Inc. stock logo
UBX
UNITY Biotechnology
-$25.99M-$1.62N/AN/AN/AN/A-246.82%-58.81%N/A

Latest UBX, CMMB, SNTI, and SKYE Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/19/2026Q2 2026
Chemomab Therapeutics Ltd. Sponsored ADR stock logo
CMMB
Chemomab Therapeutics
-$0.04-$0.27-$0.23-$0.27N/AN/A
8/14/2026Q2 2026
Skye Bioscience, Inc. stock logo
SKYE
Skye Bioscience
-$0.29-$0.27+$0.02-$0.3070N/AN/A
8/14/2026Q2 2026
Senti Biosciences, Inc. stock logo
SNTI
Senti Biosciences
-$0.33-$0.41-$0.08-$0.41N/A$0.02 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Chemomab Therapeutics Ltd. Sponsored ADR stock logo
CMMB
Chemomab Therapeutics
N/AN/AN/AN/AN/A
Skye Bioscience, Inc. stock logo
SKYE
Skye Bioscience
N/AN/AN/AN/AN/A
Senti Biosciences, Inc. stock logo
SNTI
Senti Biosciences
N/AN/AN/AN/AN/A
UNITY Biotechnology, Inc. stock logo
UBX
UNITY Biotechnology
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Chemomab Therapeutics Ltd. Sponsored ADR stock logo
CMMB
Chemomab Therapeutics
N/A
10.31
10.31
Skye Bioscience, Inc. stock logo
SKYE
Skye Bioscience
N/A
0.95
1.78
Senti Biosciences, Inc. stock logo
SNTI
Senti Biosciences
N/A
0.83
1.04
UNITY Biotechnology, Inc. stock logo
UBX
UNITY Biotechnology
N/A
1.95
1.95

Institutional Ownership

CompanyInstitutional Ownership
Chemomab Therapeutics Ltd. Sponsored ADR stock logo
CMMB
Chemomab Therapeutics
46.05%
Skye Bioscience, Inc. stock logo
SKYE
Skye Bioscience
21.09%
Senti Biosciences, Inc. stock logo
SNTI
Senti Biosciences
25.70%
UNITY Biotechnology, Inc. stock logo
UBX
UNITY Biotechnology
29.49%

Insider Ownership

CompanyInsider Ownership
Chemomab Therapeutics Ltd. Sponsored ADR stock logo
CMMB
Chemomab Therapeutics
11.91%
Skye Bioscience, Inc. stock logo
SKYE
Skye Bioscience
6.20%
Senti Biosciences, Inc. stock logo
SNTI
Senti Biosciences
3.12%
UNITY Biotechnology, Inc. stock logo
UBX
UNITY Biotechnology
5.80%
CompanyEmployeesShares OutstandingFree FloatOptionable
Chemomab Therapeutics Ltd. Sponsored ADR stock logo
CMMB
Chemomab Therapeutics
207.20 million6.34 millionNot Optionable
Skye Bioscience, Inc. stock logo
SKYE
Skye Bioscience
1135.42 million32.97 millionOptionable
Senti Biosciences, Inc. stock logo
SNTI
Senti Biosciences
431.15 million30.17 millionNot Optionable
UNITY Biotechnology, Inc. stock logo
UBX
UNITY Biotechnology
6017.21 million16.21 millionOptionable

Recent News About These Companies

Unity Stock Crashes Nearly 50% After Nasdaq Delisting Notice
June 30, 2025  |  finance.yahoo.comhttps://finance.yahoo.com/news/unity-stock-crashes-nearly-50-223255215.html
Unity Biotechnology stock plunges after Nasdaq delisting notice
June 30, 2025  |  za.investing.comhttps://za.investing.com/news/stock-market-news/unity-biotechnology-stock-plunges-after-nasdaq-delisting-notice-93CH-3774321
Unity Biotechnology Inc News (UBX) - Investing.com
June 26, 2025  |  investing.comhttps://www.investing.com/equities/unity-biotechnology-inc-news
UBX Unity Biotechnology, Inc. - Seeking Alpha
June 24, 2025  |  seekingalpha.comhttps://seekingalpha.com/symbol/UBX
HC Wainwright & Co. Downgrades Unity Biotechnology (UBX)
May 28, 2025  |  msn.comhttps://www.msn.com/en-us/money/markets/hc-wainwright-co-downgrades-unity-biotechnology-ubx/ar-AA1FAA9z
Unity Biotechnology (UBX) was downgraded to a Hold Rating at Mizuho Securities
May 18, 2025  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/UBX/pressreleases/32453730/unity-biotechnology-ubx-was-downgraded-to-a-hold-rating-at-mizuho-securities/
Bay Area biotech company Unity lays off every single worker, including CEO
May 6, 2025  |  msn.comhttps://www.msn.com/en-us/money/companies/bay-area-biotech-company-unity-once-worth-700m-lays-off-entire-remaining-workforce/ar-AA1EdgUy
Bay Area biotech company Unity, once worth $700M, lays off entire remaining workforce
May 5, 2025  |  msn.comhttps://www.msn.com/en-us/money/other/bay-area-biotech-company-unity-once-worth-700m-lays-off-entire-remaining-workforce/ar-AA1EdgUy
South San Francisco biotech company lays off entire workforce, including CEO
May 5, 2025  |  msn.comhttps://www.msn.com/en-us/money/other/biotech-company-once-valued-at-700-million-slashes-entire-workforce/ar-AA1EdIpE
Unity disbands workforce as it searches for strategic path forward, while Mammoth cuts 24 roles
May 5, 2025  |  fiercebiotech.comF
UNITY Biotechnology to Present at the ARVO 2025 Annual Meeting
May 1, 2025  |  globenewswire.comhttps://www.globenewswire.com/news-release/2025/05/01/3072287/0/en/unity-biotechnology-to-present-at-the-arvo-2025-annual-meeting.html
NEJM Evidence publishes results from Phase 2 BEHOLD study of UBX1325
April 25, 2025  |  ophthalmologytimes.comO
UNITY Biotechnology, Inc. Reports First Quarter 2025 Financial Results and Business Updates
April 22, 2025  |  globenewswire.comhttps://www.globenewswire.com/news-release/2025/04/22/3065923/0/en/unity-biotechnology-inc-reports-first-quarter-2025-financial-results-and-business-updates.html
Unity Biotechnology price target lowered to $4 from $8 at H.C. Wainwright
March 26, 2025  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/unity-biotechnology-price-target-lowered-to-4-from-8-at-h-c-wainwright-1034514135
Unity Biotechnology price target lowered to $4 from $6 at Chardan
March 26, 2025  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/unity-biotechnology-price-target-lowered-to-4-from-6-at-chardan-1034514054
Unity Biotechnology announces results from ASPIRE Phase 2b study in DME
March 25, 2025  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/unity-biotechnology-announces-results-from-aspire-phase-2b-study-in-dme-1034508884
Unity reports topline outcomes from trial of diabetic macular oedema therapy
March 25, 2025  |  msn.comhttps://www.msn.com/en-us/health/other/unity-reports-topline-outcomes-from-trial-of-diabetic-macular-oedema-therapy/ar-AA1BDWQO
UNITY Biotechnology tanks on mixed results for eye disease drug
March 25, 2025  |  thepharmaletter.comT
UBX Stock Down 29% on Mixed Results From Phase II Eye Disease Study
March 25, 2025  |  zacks.comhttps://www.zacks.com/stock/news/2434950/ubx-stock-down-29-on-mixed-results-from-phase-ii-eye-disease-study?cid=cs-stocknewsapi-ft-analyst_blog|company_news_medical_sector-2434950
UNITY Biotechnology Shares Drop 33% After Phase 2b Trial Data on UBX1325 in Diabetic Macular Edema
March 24, 2025  |  finance.yahoo.comhttps://finance.yahoo.com/news/unity-biotechnology-shares-drop-33-153658881.html

New MarketBeat Followers Over Time

Media Sentiment Over Time

Chemomab Therapeutics stock logo

Chemomab Therapeutics NASDAQ:CMMB

$2.09 +0.18 (+9.42%)
Closing price 08/19/2026 04:00 PM Eastern
Extended Trading
$2.13 +0.04 (+2.11%)
As of 04:29 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, discovers and develops therapeutics for the treatment of fibrotic and inflammatory diseases. The company's lead clinical product candidate is CM-101, a humanized monoclonal antibody had completed Phase 2a clinical trials that hinders the basic function of soluble chemokine CCL24 for the treatment of primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc). The company was formerly known as Anchiano Therapeutics Ltd. and changed its name to Chemomab Therapeutics Ltd. in March 2021. Chemomab Therapeutics Ltd. was founded in 2011 and is based in Tel Aviv, Israel.

Skye Bioscience stock logo

Skye Bioscience NASDAQ:SKYE

$0.31 -0.05 (-14.79%)
Closing price 08/19/2026 04:00 PM Eastern
Extended Trading
$0.32 +0.01 (+4.61%)
As of 05:17 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Skye Bioscience, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes cannabinoid-based molecules for the treatment of infectious diseases. The company's lead product candidate is SBI-100 used in the treatment of glaucoma and ocular hypertension. It is also developing SBI-200 to treat and manage various eye diseases, including uveitis, dry eye syndrome, macular degeneration and diabetic retinopathy. It has license agreement with university of Mississippi. The company was formerly known as Emerald Bioscience, Inc. and changed its name to Skye Bioscience, Inc. in January 2021. The company is headquartered in San Diego, California.

Senti Biosciences stock logo

Senti Biosciences NASDAQ:SNTI

$0.46 +0.03 (+7.65%)
Closing price 08/19/2026 04:00 PM Eastern
Extended Trading
$0.47 +0.01 (+2.16%)
As of 05:08 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Senti Biosciences, Inc. operates as a preclinical biotechnology company that develops next-generation cell and gene therapies engineered with its gene circuit platform technologies for various diseases. Its lead product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications. The company product candidates include SENTI-202, a Logic Gated OR+NOT off-the-shelf CAR-NK cell therapy designed to target and eliminate cancer cells while sparing the healthy bone marrow; and SENTI-301A for the treatment of hepatocellular carcinoma. It also develops SENTI-401, a Logic Gated off-the-shelf CAR-NK cell therapy designed to target and eliminate colorectal cancer/CRC cells. In addition, the company develops Tumor-Associated Antigen and Protective Antigen Paired Discovery Platform to select and validate NOT GATE antigen candidates and identify tumor-associated antigens in cancer cells. The company has a strategic collaboration with Celest Therapeutics (Shanghai) Co. Ltd for the clinical development of SENTI-301A to treat solid tumors. Senti Biosciences, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.

UNITY Biotechnology stock logo

UNITY Biotechnology NASDAQ:UBX

Unity Biotechnology, Inc., a biotechnology company, engages in the research and development of therapeutics to slow, halt, or reverse diseases of aging. The company's lead drug candidate includes UBX1325, which is Phase 2 clinical trial for the treatment of age-related diseases of the eye, including diabetic macular edema, age-related macular degeneration, and diabetic retinopathy. It also develops UBX1967 for the treatment of ophthalmologic diseases; UBX2048, a Tie2/VEGF bispecific; UBX2050, a human anti-Tie2 agonist monoclonal antibody for the treatment of eye diseases; and UBX2089, a a-Klotho hormone drug candidate for multiple neurology indications. The company was formerly known as Forge, Inc. and changed its name to Unity Biotechnology, Inc. in January 2015. Unity Biotechnology, Inc. was incorporated in 2009 and is headquartered in South San Francisco, California.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas